Assembly Biosciences (NASDAQ:ASMB) Posts Earnings Results, Beats Estimates By $0.52 EPS

Assembly Biosciences (NASDAQ:ASMB) released its earnings results on Thursday. The biopharmaceutical company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52, FiscalAI reports. The company had revenue of $13.37 million during the quarter, compared to analysts’ expectations of $8.60 million. Assembly Biosciences had a negative return on equity of 4.21% and a negative net margin of 8.98%.

Assembly Biosciences Trading Up 10.7%

Assembly Biosciences stock traded up $2.89 during mid-day trading on Thursday, hitting $29.95. The company had a trading volume of 729,230 shares, compared to its average volume of 149,038. The stock’s 50 day moving average price is $25.77 and its two-hundred day moving average price is $27.33. Assembly Biosciences has a 12 month low of $20.23 and a 12 month high of $39.71. The company has a market capitalization of $476.00 million, a PE ratio of -272.25 and a beta of 1.10.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors and hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. bought a new position in Assembly Biosciences in the 3rd quarter worth about $26,122,000. Janus Henderson Group PLC increased its stake in Assembly Biosciences by 11.3% during the 4th quarter. Janus Henderson Group PLC now owns 837,925 shares of the biopharmaceutical company’s stock valued at $28,540,000 after purchasing an additional 85,299 shares in the last quarter. Paradigm Biocapital Advisors LP bought a new stake in Assembly Biosciences during the 4th quarter valued at about $22,625,000. Vanguard Group Inc. raised its holdings in Assembly Biosciences by 97.8% in the third quarter. Vanguard Group Inc. now owns 502,112 shares of the biopharmaceutical company’s stock worth $12,854,000 after buying an additional 248,287 shares during the last quarter. Finally, Parkman Healthcare Partners LLC purchased a new position in shares of Assembly Biosciences in the third quarter worth $6,425,000. 19.92% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have commented on ASMB. Guggenheim reissued a “buy” rating and set a $43.00 price objective on shares of Assembly Biosciences in a research report on Thursday, May 28th. Wall Street Zen downgraded shares of Assembly Biosciences from a “strong-buy” rating to a “hold” rating in a research report on Saturday, May 16th. HC Wainwright reiterated a “buy” rating and issued a $50.00 price target on shares of Assembly Biosciences in a research note on Monday, May 4th. Mizuho set a $45.00 price target on shares of Assembly Biosciences and gave the company an “outperform” rating in a research report on Monday, June 15th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Assembly Biosciences currently has an average rating of “Moderate Buy” and a consensus target price of $44.00.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.